These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 21426072)

  • 1. Computational insights into the development of novel therapeutic strategies for Alzheimer's disease.
    Prabhakar R
    Future Med Chem; 2009 Apr; 1(1):119-35. PubMed ID: 21426072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Secretases as therapeutic targets for Alzheimer's disease.
    Woo HN; Baik SH; Park JS; Gwon AR; Yang S; Yun YK; Jo DG
    Biochem Biophys Res Commun; 2011 Jan; 404(1):10-5. PubMed ID: 21130746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secretase inhibitors and modulators for Alzheimer's disease treatment.
    Tomita T
    Expert Rev Neurother; 2009 May; 9(5):661-79. PubMed ID: 19402777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Production and catabolism of amyloid peptides in Alzheimer's disease].
    Checler F
    Therapie; 2010; 65(5):409-14. PubMed ID: 21144475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alzheimer's disease: from pathology to therapeutic approaches.
    Jakob-Roetne R; Jacobsen H
    Angew Chem Int Ed Engl; 2009; 48(17):3030-59. PubMed ID: 19330877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxidative balance in Alzheimer's disease: relationship to APOE, Braak tangle stage, and the concentrations of soluble and insoluble amyloid-β.
    Tayler H; Fraser T; Miners JS; Kehoe PG; Love S
    J Alzheimers Dis; 2010; 22(4):1363-73. PubMed ID: 20930272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is BACE1 a suitable therapeutic target for the treatment of Alzheimer's disease? Current strategies and future directions.
    Klaver DW; Wilce MC; Cui H; Hung AC; Gasperini R; Foa L; Small DH
    Biol Chem; 2010 Aug; 391(8):849-59. PubMed ID: 20731541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential therapeutic agents against Alzheimer's disease from natural sources.
    Park SY
    Arch Pharm Res; 2010 Oct; 33(10):1589-609. PubMed ID: 21052936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunomodulation of AβPP processing alleviates amyloid-β-related pathology in Alzheimer's disease transgenic mice.
    Arbel-Ornath M; Becker M; Rabinovich-Toidman P; Gartner M; Solomon B
    J Alzheimers Dis; 2010; 22(2):469-82. PubMed ID: 20847413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in the identification of gamma-secretase inhibitors to clinically test the Abeta oligomer hypothesis of Alzheimer's disease.
    Kreft AF; Martone R; Porte A
    J Med Chem; 2009 Oct; 52(20):6169-88. PubMed ID: 19694467
    [No Abstract]   [Full Text] [Related]  

  • 11. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo.
    Hussain I; Hawkins J; Harrison D; Hille C; Wayne G; Cutler L; Buck T; Walter D; Demont E; Howes C; Naylor A; Jeffrey P; Gonzalez MI; Dingwall C; Michel A; Redshaw S; Davis JB
    J Neurochem; 2007 Feb; 100(3):802-9. PubMed ID: 17156133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Beta- and gamma-secretases].
    Iwatsubo T
    Rinsho Shinkeigaku; 2006 Nov; 46(11):925-6. PubMed ID: 17432221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease.
    Martone RL; Zhou H; Atchison K; Comery T; Xu JZ; Huang X; Gong X; Jin M; Kreft A; Harrison B; Mayer SC; Aschmies S; Gonzales C; Zaleska MM; Riddell DR; Wagner E; Lu P; Sun SC; Sonnenberg-Reines J; Oganesian A; Adkins K; Leach MW; Clarke DW; Huryn D; Abou-Gharbia M; Magolda R; Bard J; Frick G; Raje S; Forlow SB; Balliet C; Burczynski ME; Reinhart PH; Wan HI; Pangalos MN; Jacobsen JS
    J Pharmacol Exp Ther; 2009 Nov; 331(2):598-608. PubMed ID: 19671883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An amyloid-notch hypothesis for Alzheimer's disease.
    Ethell DW
    Neuroscientist; 2010 Dec; 16(6):614-7. PubMed ID: 20592273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BACE-1 hydroxyethylamine inhibitors using novel edge-to-face interaction with Arg-296.
    Clarke B; Cutler L; Demont E; Dingwall C; Dunsdon R; Hawkins J; Howes C; Hussain I; Maile G; Matico R; Mosley J; Naylor A; O'Brien A; Redshaw S; Rowland P; Soleil V; Smith KJ; Sweitzer S; Theobald P; Vesey D; Walter DS; Wayne G
    Bioorg Med Chem Lett; 2010 Aug; 20(15):4639-44. PubMed ID: 20579874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Therapy of Alzheimer disease].
    Kovács T
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Boom in the development of non-peptidic beta-secretase (BACE1) inhibitors for the treatment of Alzheimer's disease.
    Silvestri R
    Med Res Rev; 2009 Mar; 29(2):295-338. PubMed ID: 18651582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Secretases as therapeutic targets for the treatment of Alzheimer's disease].
    Dejaegere T; de Strooper B
    Verh K Acad Geneeskd Belg; 2004; 66(1):29-58; discussion 58-9. PubMed ID: 15074081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gamma-secretase: a complex target for Alzheimer's disease.
    Lundkvist J; Näslund J
    Curr Opin Pharmacol; 2007 Feb; 7(1):112-8. PubMed ID: 17169612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BACE: Therapeutic target and potential biomarker for Alzheimer's disease.
    Evin G; Barakat A; Masters CL
    Int J Biochem Cell Biol; 2010 Dec; 42(12):1923-6. PubMed ID: 20817005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.